BioCardia, Inc. (BCDA)
| Market Cap | 14.21M +61.5% |
| Revenue (ttm) | n/a |
| Net Income | -7.34M |
| EPS | -0.74 |
| Shares Out | 15.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 236,273 |
| Open | 0.9400 |
| Previous Close | 0.9272 |
| Day's Range | 0.8700 - 0.9706 |
| 52-Week Range | 0.7500 - 1.8000 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 15.50 (+1,551.57%) |
| Est. Earnings | Nov 11, 2026 |
About BCDA
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company’s lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic he... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for BCDA stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 1,551.57% from the latest price.
News
BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
SUNNYVALE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease...
BioCardia files revised de novo pre-submission for FDA approval of Helix
BioCardia (BCDA) reported it has completed its revised Pre-Submission to FDA Center for Devices and Radiological Health, CDRH, under its Q-Submission program for the approval of its Helix Catheter for...
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
SUNNYVALE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas...
BioCardia provides update on near term milestones for CardiAMP, Helix
BioCardia (BCDA) provided an update on near term milestones. BioCardia is working towards a Shonin pre-market regulatory submission to Japan’s Pharmaceutical and Medical Device Agency in Q4 2026. The ...
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
SUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas...
BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference
SUNNYVALE, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas...
BioCardia gets FDA confirmation of Helix meeting minutes
BioCardia (BCDA) announced receipt of FDA confirmation of the outcome of its pre-submission meeting on the Helix Transendocardial Delivery Catheter System. FDA has reviewed and accepted the meeting mi...
BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval
SUNNYVALE, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas...
BioCardia Earnings Call Transcript: Q2 2026
Positive regulatory progress in Japan and the US positions CardiAMP cell therapy and Helix catheter for potential approvals, with strong financial management extending cash runway into 2027. Japanese market opportunity is significant, supported by favorable reimbursement benchmarks.
BioCardia Quarterly report: Q2 2026
BioCardia has published its Q2 2026 quarterly earnings report on August 12, 2026.
BioCardia Earnings release: Q2 2026
BioCardia released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t...
BioCardia issues letter to shareholders on 2026 priorities
BioCardia (BCDA) announced that the Company’s Chief Executive Officer, Peter Altman, issued the following letter to shareholders. “Upon completion of our recent capital raise, I am providing this upda...
BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities
SUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas...
BioCardia Announces $4.4 Million Financing
Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full f...
FDA confirms CardiAMP Heart Failure II Trial may support premarket approval
BioCardia (BCDA) announced receipt of FDA minutes from its Q-Sub Meeting with FDA Center for Biologics Evaluation and Research, or CBER, on the CardiAMP Cell Therapy System for the treatment…
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas...
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory ang...
BioCardia Transcript: A.G.P.'s Annual Virtual Healthcare Conference
Barinthus Biotherapeutics is advancing its SNAP-TI platform for autoimmune diseases, with VTP-1000 in phase I for celiac disease and a merger with Clywedog Therapeutics set to add two diabetes assets. Key clinical data are expected in 2024, and the company is funded through 2027.
BioCardia Earnings Call Transcript: Q1 2026
CardiAMP cell therapy achieved key regulatory milestones in Japan and the U.S., with strong clinical data supporting efficacy and safety. Expenses and net loss decreased year-over-year, and the company is preparing for a major market entry in Japan with a $400M opportunity.
BioCardia Earnings release: Q1 2026
BioCardia released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
BioCardia Quarterly report: Q1 2026
BioCardia has published its Q1 2026 quarterly earnings report on May 15, 2026.
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases...
BioCardia Slides: Corporate presentation
BioCardia has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, to...